Brokerages Set Humacyte, Inc. (NASDAQ:HUMA) Price Target at $6.25

Shares of Humacyte, Inc. (NASDAQ:HUMA) have received a consensus rating of “Moderate Buy” from the eight brokerages that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $6.25.

HUMA has been the subject of several recent analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Humacyte in a research note on Wednesday, July 8th. BTIG Research reaffirmed a “buy” rating and issued a $2.00 target price on shares of Humacyte in a research report on Tuesday, June 16th. Wall Street Zen cut Humacyte from a “sell” rating to a “strong sell” rating in a research note on Sunday, July 12th. TD Cowen decreased their price target on shares of Humacyte from $1.50 to $1.25 and set a “buy” rating for the company in a research report on Wednesday, June 17th. Finally, D. Boral Capital reiterated a “buy” rating and set a $25.00 price objective on shares of Humacyte in a research note on Tuesday, April 28th.

Humacyte Price Performance

HUMA stock opened at $0.67 on Friday. The company has a debt-to-equity ratio of 5.46, a quick ratio of 3.32 and a current ratio of 3.93. Humacyte has a 1 year low of $0.55 and a 1 year high of $2.84. The firm has a market cap of $148.93 million, a P/E ratio of -1.18 and a beta of 2.52. The stock has a 50-day simple moving average of $0.95 and a 200-day simple moving average of $0.95.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.01. The firm had revenue of $0.49 million for the quarter, compared to analyst estimates of $1.46 million. Humacyte had a negative return on equity of 2,914.18% and a negative net margin of 4,836.06%. On average, equities analysts predict that Humacyte will post -0.34 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Kathleen Sebelius purchased 56,818 shares of the stock in a transaction dated Tuesday, May 19th. The stock was acquired at an average cost of $0.88 per share, for a total transaction of $49,999.84. Following the acquisition, the director owned 148,025 shares of the company’s stock, valued at $130,262. The trade was a 62.30% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Dale A. Sander sold 45,887 shares of Humacyte stock in a transaction on Monday, May 18th. The stock was sold at an average price of $0.90, for a total transaction of $41,298.30. Following the completion of the transaction, the chief financial officer directly owned 267,213 shares of the company’s stock, valued at approximately $240,491.70. This represents a 14.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 3.10% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. R Squared Ltd acquired a new stake in Humacyte during the fourth quarter worth about $25,000. Atom Investors LP bought a new position in Humacyte in the fourth quarter worth about $25,000. Prudential Financial Inc. acquired a new position in Humacyte in the second quarter valued at approximately $28,000. Financial Advisors Network Inc. acquired a new position in Humacyte in the second quarter valued at approximately $28,000. Finally, Equitable Holdings Inc. bought a new position in shares of Humacyte during the third quarter valued at approximately $29,000. 44.71% of the stock is owned by institutional investors and hedge funds.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.